Hypertriglyceridemia

targets

all catalysts(0)

nothing on the calendar yet

News(6)

• FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
  The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and old…
  fda_press · 3h ago
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
  biopharma_dive · 12d ago
• Biotechs bring big launches and pharma rivalries into Q2 earnings period
  With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
  biospace · 21d ago
• FDA panel confronting peptide controversy
  Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
  stat · 27d ago
• Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
  To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
  biopharma_dive · 28d ago
• Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
  With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…
  biospace · 28d ago